SK Group has reached a long-term strategic alliance with Roivant Sciences to develop new drugs based on the US firm’s targeted protein degradation platform, which uses artificial intelligence technology to improve the efficiency of the development process.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?